Mitoquinone · MitoQ10 · Mitochondria-Targeted CoQ10
10 mg · vegan · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
MitoQ is a mitochondria-targeted antioxidant formed by covalently attaching ubiquinone (CoQ10) to a lipophilic triphenylphosphonium cation. This targeting moiety exploits the large mitochondrial membrane potential to concentrate CoQ10 100–500-fold inside mitochondria, precisely where reactive oxygen species are generated.
Once inside mitochondria, MitoQ is reduced by complex II to its active ubiquinol form, where it scavenges superoxide and lipid peroxides. In diabetic kidney disease, MitoQ restores Nrf2/PINK1-mediated mitophagy, reduces tubular apoptosis, and lowers albuminuria. In pancreatic β-cells, it prevents ER stress and restores glucose-stimulated insulin secretion.
Adults with metabolic syndrome, type 2 diabetes, or those seeking mitochondrial antioxidant support for aging. Also studied for Parkinson's and multiple sclerosis.
No major contraindications at 10 mg/day. High doses may cause mitochondrial uncoupling. Not recommended in pregnancy. Discontinue before surgery.
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Morning dosing aligns with circadian metabolic activity
✓ Take with breakfast to reduce GI discomfort and improve absorption
Once inside mitochondria, MitoQ is reduced by complex II to its active ubiquinol form, where it scavenges superoxide and lipid peroxides.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Insomnia cohort (n≈60, PSQI scale)
PSQI score <5 = good sleep quality. Lower is better.
98 T2D patients + 71 controls
→ MitoQ (0.5 µM, 30 min) decreased mitochondrial ROS, increased GPX-1, reduced PMN adhesion, and lowered NFκB-p65 and TNF-α in leukocytes from type 2 diabetic patients
db/db mice
→ MitoQ restored PINK1/Parkin-mediated mitophagy, reversed mitochondrial fragmentation, reduced tubular apoptosis, and decreased urinary ACR and 8-OHdG in diabetic kidney disease
INS-1E cells
→ MitoQ increased glucose-stimulated insulin secretion, prevented ROS overproduction, restored GSH levels, and reduced ER stress markers (GRP78, P-eIF2α) and NFκB-p65 under high glucose
B · Strong preclinical and ex vivo human cell data for diabetes, kidney disease, and pancreatic β-cell protection. Phase II trials in Parkinson's and MS showed safety but mixed efficacy. The targeting mechanism is pharmacologically elegant and well-validated
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: Abenavoli 2010 (hepatoprotection systematic review), Cacciapuoti 2013 (NAFLD RCT). richResearch section contains study filters.
How to use MitoQ specifically for Fatigue — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of MitoQ — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about MitoQ — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on MitoQ — context the structured blocks above don't capture.
MitoQ is a mitochondria-targeted antioxidant formed by covalently attaching ubiquinone (CoQ10) to a lipophilic triphenylphosphonium cation. This targeting moiety exploits the large mitochondrial membrane potential to concentrate CoQ10 100–500-fold inside mitochondria, precisely where reactive oxygen species are generated.
Once inside mitochondria, MitoQ is reduced by complex II to its active ubiquinol form, where it scavenges superoxide and lipid peroxides. In diabetic kidney disease, MitoQ restores Nrf2/PINK1-mediated mitophagy, reduces tubular apoptosis, and lowers albuminuria. In pancreatic β-cells, it prevents ER stress and restores glucose-stimulated insulin secretion.
Who benefits most
Adults with metabolic syndrome, type 2 diabetes, or those seeking mitochondrial antioxidant support for aging. Also studied for Parkinson’s and multiple sclerosis.
Dosage and form
10 mg is the typical effective range. Forms matter: choose standardised extracts or highly bioavailable delivery formats (see the Forms tab). Take as directed.
Side effects and cautions
Mild GI upset, especially on empty stomach. Avoid if you: No major contraindications at 10 mg/day. High doses may cause mitochondrial uncoupling. Not recommended in pregnancy. Discontinue before surgery..
The evidence
Human clinical trials and mechanistic research support the use of MitoQ for its primary indication. See the Research tab for full citations and study summaries.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
